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Abstract
The vascular endothelial growth factor (VEGF) pathway is a clinically
validated antiangiogenic target for non-small cell lung cancer
(NSCLC). However, some contradictory results have been reported
on the biological effects of antiangiogenic drugs. In order to evalu-
ate the efficacy of these drugs in NSCLC histological subtypes, we
analyzed the anticancer effect of two anti-VEGFR2 therapies (suniti-
nib and DC101) in chemically induced mouse models and tumor-
grafts of lung adenocarcinoma (ADC) and squamous cell carcinoma
(SCC). Antiangiogenic treatments induced vascular trimming in both
histological subtypes. In ADC tumors, vascular trimming was accom-
panied by tumor stabilization. In contrast, in SCC tumors, anti-
angiogenic therapy was associated with disease progression and
induction of tumor proliferation. Moreover, in SCC, anti-VEGFR2
therapies increased the expression of stem cell markers such as
aldehyde dehydrogenase 1A1, CD133, and CD15, independently of
intratumoral hypoxia. In vitro studies with ADC cell lines revealed
that antiangiogenic treatments reduced pAKT and pERK signaling
and inhibited proliferation, while in SCC-derived cell lines the same
treatments increased pAKT and pERK, and induced survival. In con-
clusion, this study evaluates for the first time the effect of antian-
giogenic drugs in lung SCC murine models in vivo and sheds light
on the contradictory results of antiangiogenic therapies in NSCLC.
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Introduction
Lung cancer is the third leading cause of death in high-income
countries (Lopez et al, 2006), and it remains the leading cause of
cancer-related death worldwide (Siegel et al, 2013) with about
1.4 million deaths annually across the world (Jemal et al, 2011).
Non-small cell lung cancer (NSCLC) is the most common type of
lung cancer accounting for approximately 85% of lung cancers.
NSCLC can be subdivided into two main histological subtypes:
adenocarcinoma (ADC) and squamous cell carcinoma (SCC) that
account for 50 and 30% of NSCLC cases, respectively (Langer et al,
2010). In the clinical practice, advanced NSCLC can be treated with
cytotoxic chemotherapy in combination with targeted agents that
block two main molecular pathways: cell signaling mediated by the
epithelial growth factor receptor (EGFR) and angiogenesis mediated
by the vascular endothelial growth factor (VEGF). The efficacy and
safety of antiangiogenic therapies in NSCLC appear to be closely
associated with the histological subtype of the tumor. Hence, the
administration of bevacizumab, an anti-VEGF monoclonal antibody,
is restricted to non-squamous patients (Johnson et al, 2004). How-
ever, the clinical benefit of bevacizumab is modest and episodes of
resistance have been reported (Ebos & Kerbel, 2011). Furthermore,
preclinical studies on pancreatic carcinoma, breast cancer, mela-
noma, and glioblastoma have evidenced a detrimental role of anti-
angiogenic agents related to an increase in their metastatic potential
(Ebos et al, 2009; Paez-Ribes et al, 2009; Sennino et al, 2012). In an
effort to develop more effective treatments, new antiangiogenic
agents, such as the multi-tyrosine kinase inhibitors sunitinib and so-
rafenib, are under clinical evaluation (Reckamp, 2012). Interest-
ingly, the phase III ESCAPE trial demonstrated greater mortality
rates in SCC patients of the sorafenib arm (Scagliotti et al, 2010).
Moreover, we recently reported data on the prognostic role of the
VEGF pathway in early ADC and SCC of the lung, which stress the
different behavior of both histologies. Specifically, we showed that
high combined expression of VEGF, VEGFR1, and VEGFR2 in tumor
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cells is associated with good prognosis in early-stage SCC patients,
but not in ADC (Pajares et al, 2012). Currently, there are hundreds
of clinical trials under way to assess the use of VEGF-pathway-
targeted drugs in a variety of tumors, and thousands of lung can-
cer patients are expected to be enrolled in these clinical trials in
the next 5 years (http://clinicaltrials.gov). In these circumstances,
a rigorous assessment of the significance of the VEGF pathway on
the two main histologies of NSCLC and the biological response to
antiangiogenic drugs in NSCLC is mandatory. For this purpose,
mouse models of NSCLC are especially useful since the efficacy of
new drugs can be tested in lung cancer tumors of specific histol-
ogy. In addition, mouse models can be used simultaneously to
human clinical trials following the rationale of co-clinical trials
(Chen et al, 2012).
In the present study, we evaluated the efficacy of two anti-VEG-
FR2 compounds (sunitinib and DC101) on chemically induced
mouse models of specific lung cancer subtypes: the urethane-
induced mouse model of pulmonary ADC and the N-nitroso-tris-
chloroethylurea (NTCU)-induced mouse model of lung SCC. We also
analyzed the impact of VEGFR2 blockade on ADC and SCC tumor-
grafts. Analyses of angiogenesis, proliferation, apoptosis, and stem
cell marker expression demonstrated contrasting effects of antiangi-
ogenic drugs in these two histological subtypes.
Results
Chemically induced mouse tumor models recapitulate specific
histological subtypes of human lung cancer
Molecular and histopathological analysis of the urethane-induced
model of pulmonary ADC and the NTCU-induced model of SCC was
performed. The ADC model elicits neoplastic lesions with glandular
differentiation and immunohistochemical staining of TTF-1 that
recapitulate the histopathological features of human lung ADC (Sup-
plementary Figs S1A,C,E). In the NTCU model, lung lesions were
centrally located and frequently associated with bronchioles. Simi-
larly to human SCC, intercellular bridges and keratin pearls could
be observed (Supplementary Fig S1B). The squamous differentiation
was confirmed by p63 staining (Supplementary Figs S1D,F). Both
ADC and SCC tumors expressed VEGF and VEGFR2 (Supplementary
Fig S2A).
Differential tumor response to VEGFR2 inhibition in ADC and SCC
To determine the antitumor effect of anti-VEGFR therapies, mice
bearing urethane-induced ADC or NTCU-induced SCC tumors
were treated with sunitinib, a multi-tyrosine kinase inhibitor that
blocks VEGF receptors. As sunitinib action is not restricted to
VEGF receptors, we also tested the effect of a specific blocking
antibody against murine VEGFR2 (DC101). The blockade of VEG-
FR2 by these antiangiogenic drugs was verified by the decrease in
pVEGFR2 staining in endothelial and tumor cells (Supplementary
Fig S2B). Furthermore, the antiangiogenic effect of sunitinib and
DC101 was demonstrated by a significant reduction in CD31
staining in both ADC and SCC (Supplementary Fig S3). Central
necrotic areas were identified in some lesions following antiangio-
genic treatments (Supplementary Figs S4A,B). No bleeding
episodes or fatal events were observed in mice treated with suni-
tinib or DC101.
Respiratory-gated micro-CT imaging was used to determine
the effect of anti-VEGFR therapies on lung tumor progression.
Longitudinal evaluation of treatment response was performed
according to the criteria used for the assessment of response in
human cancers (RECIST), using a threshold of 20% change in tumor
diameter or tumor area as cutoff point to differentiate between pro-
gressive disease and stabilization of the disease (Eisenhauer et al,
2009). In ADC, tumor stabilization was achieved in mice treated with
sunitinib (Fig 1A) or DC101 (Fig 1B). Conversely, mice bearing SCC
tumors showed progression of the disease in sunitinib- (Fig 1C) and
DC101-treated groups (Fig 1D). Mice receiving DC101 therapy earlier
(8 weeks of NTCU treatment) also showed progression of the disease
(Supplementary Fig S5). Therefore, in contrast to ADC, anti-VEGFR2
drugs failed to prevent tumor growth in the SCC mouse model.
Inhibition of VEGFR2 differentially affects ADC and SCC tumor
cell proliferation
We next evaluated the effect of anti-VEGFR2 therapies on cell prolif-
eration and apoptosis. In the ADC model, both sunitinib- and DC101-
treated tumors showed a significant reduction in Ki67 staining when
compared to their vehicle-treated counterparts (Figs 2A,B). Quantifi-
cation of cleaved caspase 3 in ADC showed a significant increase in
apoptosis in the sunitinib- (Fig 2C) and DC101-treated groups
(Fig 2D). Contrastingly, in mice bearing lung SCC, sunitinib signifi-
cantly increased tumor cell proliferation (Fig 2E). This increase in
proliferation was also identified in DC101-treated animals (Fig 2F).
The percentage of tumor-apoptotic cells also increased in the suniti-
nib group (Fig 2G), but not in the DC101 treatment (Fig 2H).
The contrasting response to VEGFR2 inhibitors is also observed
in ADC and SCC tumorgrafts
To further explore the contrasting efficacy of VEGFR2 inhibitors in
ADC and SCC, subcutaneous implantation models were carried out
with cell lines derived from urethane-induced tumors (UN-ADC12)
and NTCU-induced tumors (UN-SCC680). Tumorgrafts bearing mice
were treated with sunitinib or DC101. The antiangiogenic effect of
the drugs was demonstrated by the evaluation of CD31 expression
in tumorgrafts (Supplementary Fig S6). Tumor progression was
evaluated by the assessment of changes in tumor volume longitudi-
nally over time. UN-ADC12 tumorgrafts were significantly smaller
in sunitinib- and DC101-treated groups than in the control group
(Fig 3). In accordance with the results obtained in the urethane
model, subsequent analysis of Ki67 and cleaved caspase 3 staining
demonstrated that both sunitinib and DC101 treatments significantly
reduced proliferation and increased apoptosis in ADC tumor cells
(Fig 3). Moreover, histological analyses of the lungs, liver, spleen,
and kidneys evidenced the presence of distant metastases (mainly to
the lungs) that were significantly reduced with the anti-VEGFR2
treatments (Supplementary Fig S7). Overall survival was signifi-
cantly prolonged in sunitinib- and DC101-treated mice as compared
to control groups (Supplementary Figs S8A,B).
In mice bearing the SCC-derived UN-SCC680 tumorgrafts, no dif-
ferences in tumor volume were found between sunitinib- or DC101-
treated and control groups (Fig 3). Remarkably, both treatments
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significantly increased SCC tumor cell proliferation and apoptosis
(Fig 3). These results confirm the hyperproliferative response
observed in the in vivo NTCU model and suggest that a balance
between proliferation and apoptosis in anti-VEGFR2-treated mice
prevents tumor overgrowth as compared to controls. Moreover, no
significant differences in overall survival were observed between
groups (Supplementary Figs S8C,D). No distant metastases were




Figure 1. Sunitinib induces a differential tumor response between adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
A, B In the urethane-induced ADC mouse model, sunitinib (A) and DC101 (B) treatments stabilized tumor growth; Top: Waterfall plots of tumor response to sunitinib
(A) or DC101 (B) treatments of ADC-bearing mice (the bold line at 20% indicates disease progression as defined by response in human cancers criteria). Tumor
diameter change was calculated for each mouse taking the initial size of every lesion as reference. Each column represents the average tumor diameter change
in each mouse after 5 weeks of treatment. Bottom: The pre- and post-treatment mean size for each group is presented in a line plot. Representative micro-CT
images of ADC tumors show the progression of the disease in the control group and the stabilization of tumor growth in the sunitinib group. Lung ADC lesions
(arrows) are shown at higher magnification (inset). Data are presented as mean  standard error.
C, D In the N-nitroso-tris-chloroethylurea-induced SCC model disease progression was observed. Top: Waterfall plots of SCC tumor response to sunitinib (C) or DC101
(D) treatments showing the percentage of area change for each mouse. Bottom: The pre- and post-treatment mean tumor area for each group is presented in a
line plot. Representative micro-CT images of SCC tumors (dotted line) show the progression of the disease in the sunitinib and vehicle (control) groups. Data are
presented as mean  standard error.
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Anti-VEGFR2 treatments result in opposite survival and signaling
effects in mouse ADC and SCC cell lines
To determine whether antiangiogenic treatments could directly
affect cell survival independently of tumor microenvironment, we
examined the effect of antiangiogenic drugs (sunitinib and DC101)
on survival in cell lines derived from urethane-induced ADC
(UN-ADC12 and UN-ADC18) and NTCU-induced SCC tumors
(UN-SCC679 and UN-SCC680). In ADC cell lines, sunitinib treatment
caused a modest inhibition of tumor cell proliferation (Fig 4A).
However, sunitinib dramatically induced proliferation of SCC cell
lines within the concentration range between 33.3 nM and 1 lM,
whereas higher concentrations of sunitinib abolished cell prolifera-





Figure 2. VEGFR2 blockade differentially affects adenocarcinoma (ADC) and squamous cell carcinoma (SCC) tumor cell proliferation and apoptosis.
A–D Representative images of immunohistochemical analysis of Ki67 and cleaved caspase 3 in ADC tumor-bearing mice. In the urethane-induced ADC model, sunitinib
(A) and DC101 (B) reduced the tumor cell proliferation index. Increased tumor apoptosis as measured by cleaved caspase 3 staining was observed in sunitinib (C)
and DC101 (D) groups. Scale bar, 25 m. Data are presented as mean  standard error.
E–H Representative images of immunohistochemical analysis of Ki67 and cleaved caspase 3 in SCC. Sunitinib (E) and DC101 (F) treatments in SCC tumors significantly
induced proliferation as compared to vehicle. The percentage of apoptotic cells was increased in the sunitinib group (G), but not in the DC101 group (H). Scale
bar, 25 lm. Data are presented as mean  standard error.
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onstrated the prosurvival effect of sunitinib and DC101 in SCC cell
lines (Figs 4B,C). These results are in concordance with the in vivo
experiments that demonstrated a higher tumor proliferative rate in
SCC. We finally assessed the effect of VEGFR2 blockade on cell
signaling. Consistent with the survival data presented above, suniti-
nib and DC101 treatments reduced the activation of AKT and ERK in
ADC cell lines (Fig 4D). However, the phosphorylation levels of
ERK and AKT were increased in SCC cell lines (Fig 4E) after suniti-
nib and DC101 treatments. Taken together, our results suggest that
the opposite effects caused by the anti-VEGFR treatments in ADC
and SCC tumor cells are associated with differences in signaling
pathway activation.
Antiangiogenic treatments increase the expression of stem cell
markers in the SCC model
Sunitinib increases the population of aldehyde dehydrogenase 1A1
(ALDH1A1)-positive cancer stem cells in breast cancer xenografts
Figure 3. VEGFR2 inhibitors induce contrasting responses in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) tumorgrafts. Immunodeficient mice
bearing subcutaneous ADC or SCC tumors (using UN-ADC12 or UN-SCC680 cell lines, respectively) were treated with: sunitinib (40 mg/kg) or vehicle (PBS), or DC101 (40 mg/
kg) or isotype antibody (40 mg/kg). Treatment was initiated at day 17 post-injection in the ADC model and at day 25 post-injection in the SCC model. The quantification of
Ki67 and cleaved caspase 3 expression after sunitinib and DC101 treatments was performed automatically. Data are presented as mean  standard error (n = 6 for all
groups).
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(Conley et al, 2012). In order to evaluate whether sunitinib
increases this cell population in lung cancer, we analyzed the pres-
ence of ALDH1A1-positive cells in tumors from mice bearing ure-
thane-induced ADC and NTCU-induced SCC. We also analyzed the
expression of CD133 and CD15, other two markers that have been
associated with stemness in lung cancer cells (Bertolini et al, 2009;
Nolte et al, 2013). In the ADC model, stem cell markers expression
was very low and no significant differences between groups were
observed (Supplementary Fig S9A). In NTCU-induced SCC-bearing
mice, tumor expression of ALDH1A1, CD133, and CD15 measured
by immunohistochemistry was significantly increased following
sunitinib treatment (Figs 5A,C,E). These results were further con-
firmed by real-time PCR (Figs 5B,D,F). After DC101 treatment, the
mRNA expression of the three stem cell markers was significantly
higher in DC101-treated SCC tumors, although only significant dif-
ferences in CD133 were found when protein expression was evalu-
ated (Fig 6). We next sought to evaluate the correlation between
tumor hypoxia and stem cell markers, since hypoxia has been
reported to be associated with the induction of ALDH1A1 and
CD133 in some experimental models (Conley et al, 2012; Iida et al,
2012). Tumor hypoxia was measured by immunohistochemistry as
the percentage of carbonic anhydrase IX (CA-IX)-positive cells and
by real-time quantitative PCR (qPCR) as the expression of
hypoxia-inducible factor-1a (HIF-1a). The expression of hypoxic
markers was higher in mice treated with anti-VEGFR2 therapies
(Supplementary Fig S10A), although differences were only statisti-
cally significant when CA-IX expression was analyzed. CA-IX expres-
sion did not correlate with ALDH1A1, CD133, or CD15 staining
quantified in the same tumor areas of serial sections (Supplementary
Figs S9B,C). Confirming this observation, no correlation between
the expression of HIF-1a mRNA and ALDH1A1, CD133, or CD15
mRNA expression was found (Supplementary Fig S9D). Even when
the correlation analyses were performed separately between control
and treated mice (Supplementary Fig S10B), no correlation was
found between hypoxia and stem cell markers. In conclusion, in the
NTCU-induced SCC model, antiangiogenic treatments induce the
expression of stem cell markers in a hypoxia-independent manner.
Discussion
Antiangiogenic drugs targeting the VEGF signaling pathway have
been approved in the treatment for NSCLC patients by means of suc-






Figure 4. Anti-VEGFR2 therapies induce opposite effects on cell survival and VEGFR2 downstream signaling in vitro.
A MTT cell proliferation assay of adenocarcinoma (ADC)-(UN-ADC12 and UN-ADC18) and squamous cell carcinoma (SCC)-(UN-SCC679 and UN-SCC680)
tumor-derived cell lines treated with sunitinib. Data are presented as mean  standard error.
B, C Colony formation assay of ADC- and SCC tumor-derived cell lines treated with sunitinib (B) or DC101 (C). Data are presented as mean  standard error.
D, E Representative western blotting images of pAKT and pERK levels showing a differential activation of VEGFR2 downstream signaling in ADC (D) and SCC (E) cell lines.
Source data are available for this figure.
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hen et al, 2007; Reck et al, 2009). However, some limitations asso-
ciated with antiangiogenic inhibitors have been reported (Ebos et al,
2009; Paez-Ribes et al, 2009; Casanovas, 2012; Conley et al, 2012;
Van der Veldt et al, 2012). We recently showed that the prognostic
relevance of the VEGF pathway in NSCLC is dependent on tumor
histology (Pajares et al, 2012). Those results, together with the
reported genetic differences between ADC and SCC histologies (Sos
et al, 2009; Mountzios et al, 2010; Takahashi et al, 2010; Weiss
et al, 2010; Hammerman et al, 2011, 2012; Imielinski et al, 2012;
Sos & Thomas, 2012), led us to explore the efficacy of anti-VEGF/
VEGFR therapy in clinically relevant mouse models that resemble
the most represented NSCLC histologies. The choice of these models
was based on the necessity to generate pure histological subtypes.
Although there are several well-established genetically modified
mouse models that resemble lung ADC tumors (Kwon & Berns,
2013), there are no validated transgenic mouse models that
uniquely reproduce SCC tumors (Farago et al, 2012; You et al,
2013). In fact, the NTCU model is at present the only validated
mouse model of lung SCC.
In mouse ADC tumors, we have demonstrated the therapeutic
benefit of sunitinib and the monoclonal antibody DC101 against
mouse VEGFR2. These results are in accordance with those reported
in the K-RAS conditional mutant mouse model of lung ADC treated
with sunitinib (Gandhi et al, 2009) and in the urethane mouse
model treated with DC101 (Karoor et al, 2010). We have also
demonstrated the therapeutic benefit of anti-VEGFR2 therapies in
metastatic ADC tumorgrafts. VEGFR2 blockade was associated with
a reduction in tumor cell proliferation and overall survival benefit.
In contrast, we show for the first time that VEGFR2 blockade by
sunitinib and DC101 leads to tumor progression in two experimental
models of mouse SCC: a chemically induced mouse model of SCC and
a model of SCC tumorgraft. Interestingly, VEGF pathway inhibition
results in the hyperproliferation of SCC tumor cells in both models.
This is supported by our in vitro observations that anti-VEGFR2
therapies induce cell proliferation and survival in SCC cell lines.
These results demonstrate the relevance of the VEGF-VEGFR2 auto-
crine pathway in lung tumors, a circumstance that has been recently




Figure 5. Sunitinib induces the expression of stem cell markers in squamous cell carcinoma tumors.
A, B ALDH1A1 expression. Representative images of immunohistochemical analysis of ALDH1A1 in vehicle (control) and sunitinib-treated mice (A). Automatic
quantification of tumor cell staining was performed. The mRNA expression of ALDH1A1 was evaluated by quantitative PCR (B). Each value was normalized to the
reference gene (GUSB) and the expression in paired normal tissue was used for calibration. Scale bar, 25 lm. Data are presented as mean  standard error.
C, D CD133 expression analysis. Representative analysis of CD133 expression by immunohistochemistry (C) and by quantitative PCR (D). Each value was normalized to
the reference gene (GUSB) and the expression in paired normal tissue was used for calibration. Scale bar, 25 m. Data are presented as mean  standard error.
E, F CD15 expression analysis by immunohistochemistry (E) and by quantitative PCR (F). Each value was normalized to the reference gene (GUSB) and the expression
in paired normal tissue was used for calibration. Scale bar, 25 lm. Data are presented as mean  standard error.
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cally demonstrated in human lung ADC cell lines (Chatterjee et al,
2013). More importantly, we demonstrate for the first time that
anti-VEGFR therapies have protumoral effects on mouse models of
lung SCC. In contrast, these therapies are able to control tumor pro-
gression in lung ADC models. Our study also suggests that differen-
tial cell signaling responses after VEGFR2 blockade could be one of
the mechanisms underlying these contrasting differences on
antitumor efficacy. In fact, although some reports demonstrate an
association between VEGFR2 blockade and decrease in cell prolifer-
ation (Masood et al, 2001; Wu et al, 2007), in some ovarian and
pancreatic cancer cell lines VEGFR2 knockdown enhances prolifera-
tion (Adham et al, 2010; Silva et al, 2011). Indeed, Chatterjee et al
(2013)have reported that VEGFR2 knockdown in the EGFR-mutated
H1975 human cell line of lung ADC is associated with higher
proliferation and activation of ERK signaling in xenograft models.
Interestingly, while urethane-induced ADC model is associated with
K-RAS mutations (Fritz et al, 2010), this gene has not been found
altered in NTCU-induced SCC tumors (Wang et al, 2004). Taken
together, these data suggest that the specific mutation status under-
lying histological subtypes may be an important mediator of the
response to antiangiogenic therapies. Furthermore, our data demon-
strate that antiangiogenic drugs not only induce cell survival in
SCC, but also increase the stem-like features of SCC tumors. Similar
results were found in a breast cancer preclinical model after suniti-
nib treatment (Conley et al, 2012). The low expression of the three
stem cell markers analyzed in this study in the urethane-induced
ADC model reinforces the differences between ADC and SCC.
Accordingly, heterogeneity of stem cell-related markers according
to tumor subtype has been also described in other tumors (Park
et al, 2010). In addition, it has been proposed that hypoxia may
drive tumor growth through the expansion of cancer stem cells in
severely hypoxic regions in tumors (Keith & Simon, 2007). In our
model of SCC, antiangiogenic treatments induce the expression of
stem cell markers independently of hypoxia. Our findings further
link the induction of a stem cell population and the hyperprolifera-
tion of tumor with a lack of response to antiangiogenic drugs in
SCC. These results, together with our previous observation in
NSCLC patients that high VEGF pathway in early-stage SCC tumors
correlates with good prognosis, emphasize the importance of a
detailed preclinical evaluation of new antiangiogenic therapies.
Moreover, our data support the need for precaution when consider-
ing the possibility of enrolling SCC patients in clinical trials evaluat-
ing antiangiogenic drugs.
Materials and Methods
Chemically induced animal models and treatment schedules
All animal experiments were conducted in accordance with the
protocols approved by the Institutional Animal Care Committee.
For the chemically induced ADC model, A/J mice (Harlan Labo-
ratories, Derby, UK) at 8 weeks of age received i.p. injection of ure-
thane (Sigma-Aldrich, Madrid, Spain) in 0.9% saline at a dose of
1 g/kg body weight. Twelve weeks after injection, lung lesions were
evaluated by respiratory-gated micro-CT analysis as previously
described (Artaechevarria et al, 2010). For the SCC model, 8-week-
old A/J mice were treated with 0.04 M N-nitroso-tris-chloroethylu-
rea (NTCU; Toronto Research Chemicals, Inc., Toronto, ON, Can-
ada) as previously described (Rehm et al, 1991; Wang et al, 2004).
NTCU was applied by skin painting twice a week for 20 weeks.
Adenocarcinoma and SCC tumor-bearing mice were subjected to
pre-treatment micro-CT analysis, randomly separated into four
experimental groups, and treated over a time period of 5 weeks with
the following scheme: (i) sunitinib malate (LC Laboratories,
Woburn, MA, USA) at a dose of 40 mg/kg body weight was admin-
istered daily by oral gavage; (ii) oral gavage with phosphate-buf-
fered saline (vehicle control) was applied to the control group for
sunitinib; (iii) the monoclonal antibody against murine VEGFR2
(DC101; Bioxcell, West Lebanon, NH, USA) was i.p. injected at a
dose of 40 mg/kg body weight twice a week; (iv) mice in the control




Figure 6. DC101 treatment induces the expression of stem cell markers
in squamous cell carcinoma tumors. The expression of stem cell markers
ALDH1A1, CD133, and CD15 was analyzed by immunohistochemistry (A, C, E) and
quantitative PCR (qPCR) (B, D, F). Automatic quantification of tumor cell staining
was performed. For qPCR, each value was normalized to the reference gene
(GUSB) and the expression of paired normal tissue was used as calibrator
sample. Data are presented as mean standard error. The expression of stem cell
markers ALDH1A1, CD133, and CD15 was analyzed by immunohistochemistry (A,
C, E) and quantitative PCR (qPCR) (B, D, F). Automatic quantification of tumor cell
staining was performed. For qPCR, each value was normalized to the reference
gene (GUSB) and the expression of paired normal tissue was used as calibrator
sample. Data are presented as mean  standard error.
A, B ALDH1A1 expression.
C, D CD133 expression
E, F CD15 expression
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40 mg/kg body weight twice a week. Treatment schemes and doses
of these drugs were chosen according to previous reports that dem-
onstrated inhibition of VEGFR2 in animal models (Prewett et al,
1999; Christensen, 2007). For the SCC model, an additional DC101
treatment group in early SCC tumors was included. In brief, NTCU
was applied for only 8 weeks and DC101 was injected for 5 weeks
as previously described. Mice were subjected to an additional
micro-CT to evaluate the response to treatment. Subsequently, mice
were sacrificed and lungs were fixed in 4% buffered formalin for
24 h and paraffin-embedded.
Micro-CT images were calibrated to Hounsfield units using a
water phantom. Tumor measurements (tumor diameter and tumor
area) were performed by two independent observers using the
ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Response evaluation criteria in human solid tumors (RECIST) were
used to evaluate treatment response (Eisenhauer et al, 2009).
Mouse cell line establishment
Two mouse SCC (UN-SCC679 and UN-SCC680) and two mouse
ADC (UN-ADC12 and UN-ADC18) cell lines were established in
our laboratory following the protocol previously published by Oie
et al (1996) with minor modifications. Briefly, ADC tumors were
induced by urethane injection and SCC tumors were induced by
NTCU treatment, as described above. Lungs were excised after
sacrifice and tumor cells were separated by the mechanical spil-
lout method. Cells were cultured in ACL4 media (Oie et al, 1996)
supplemented with 5% fetal bovine serum and penicillin–strepto-
mycin–fungizone. Adherent colonies were cultured for at least 25
passages and subcutaneously injected in the flanks of 6-week-old
female BALB/c Nu/Nu mutant athymic mice (UN-SCC679, UN-
ADC12, and UN-ADC18 cell lines) or BALB/c-Rag2/-IL2cc/
immunodeficient mice (UN-SCC680). Tumorgrafts were excised as
described above, and adherent colonies were cultured in ACL4
media.
Subcutaneous tumorgraft assays
UN-SCC680 and UN-ADC12 cells (2 × 106 cells) in an exponential
growth phase were subcutaneously injected in the flanks of 5- to 7-
week-old female BALB/c-Rag2/-IL2cc/ immunodeficient mice
(n = 6 per experimental condition). Tumor size was measured
externally using a precision caliper, and tumor volume (V) was cal-
culated using the following equation: V = 0.50 × width2 × length.
When tumors reached an average volume of 200 mm3 (UN-SCC680)
or 700 mm3 (UN-ADC12), treatment was initiated. In brief, mice
were treated with (i) 40 mg/kg sunitinib malate or (ii) PBS, both
treatments daily oral gavage administered; (iii) 40 mg/kg DC101 or
(iv) 40 mg/kg isotype antibody, both treatments administered by
i.p. injection twice a week.
Experimental endpoint was accomplished when tumors reached
1.7 cm in diameter. Tumorgrafts, lungs, liver, spleen, and kidneys
were harvested and fixed overnight in 4% buffered formalin,
embedded in paraffin, and sectioned. The presence of tumor metas-
tases was determined by hematoxylin and eosin (H/E) staining and
histological examination. Lung H/E sections from the UN-ADC12
tumorgraft model were scanned, and tumor area was quantified
using the ImageJ software.
Cell proliferation and survival assays
MTT (Sigma-Aldrich) assay was used to evaluate cell proliferation.
Cells were seeded at 1 × 103 cells per well in 96-well plates and
allowed to attach overnight. Cells were treated with PBS or sunitinib
(at concentrations ranging from 33.3 nM to 100 lM) for 48 h, and
cell proliferation was measured by MTT conversion. Absorbance
was measured at 540/690 nm on a Sunrise plate reader (Tecan,
M€annedorf, Switzerland). The experiments were done in quintupli-
cate and repeated at least three times.
For clonogenic assays, cells were harvested and seeded in six-well
plates (400 cells/well) and treated with sunitinib (1, 20, 100, 200 nM,
or 1 lM), DC101 (1, 20, or 100 lg/ml), or vehicle: PBS for sunitinib
control and rat IgG1 antibody (100 lg/ml) for DC101 control. After
14 days, cells were fixed in 4% buffered formalin for 30 min and
stained with crystal violet to determine colony formation. All experi-
ments were performed in triplicate and repeated at least three times.
Western blotting
UN-ADC12, UN-ADC18, UN-SCC679, and UN-SCC680 cell lines were
seeded at 300 000 cells per well in 6-well plates and allowed to
attach overnight. Cells were treated with PBS, sunitinib (at
concentrations ranging from 100 nM to 1 lM), DC101 (100 lg/ml),
or rat IgG1 antibody (100 lg/ml) for 48 h. Cells were lysed and total
proteins were extracted as previously described (Catena et al,
2010). Twenty lg of total protein from each lysate was boiled at
95°C for 5 min, separated by SDS–PAGE under reduced conditions
(5% 2-mercaptoethanol), and transferred onto nitrocellulose mem-
branes. The membranes were subsequently blocked in 5% defatted
milk–PBS for 1 h and incubated overnight at 4°C with the following
primary antibodies: anti-AKT (1:1000; 9272; Cell Signaling Technol-
ogy, Beverly, MA, USA), anti-pAKT (1:1000; 9271; Cell Signaling
Technology), anti-ERK (1:1000; 9102; Cell Signaling Technology),
and anti-pERK (1:1000; 9101; Cell Signaling Technology). Blots were
then incubated with a horseradish peroxidase-linked secondary anti-
body (1:2000; Amersham Pharmacia Biotech, Little Chalfont, UK)
and developed by chemiluminescence with Lumilight plus kit
(Roche diagnostics, Burgess Hill, UK).
Immunohistochemistry
Immunohistochemistry of formalin-fixed, paraffin-embedded sec-
tions was performed using a Dako Autostainer (Dako, Madrid,
Spain). Antibodies used for immunostaining were anti-VEGF (1:100;
Sc-152 rabbit IgG; Santa Cruz Biotechnology, Heidelberg, Germany),
anti-VEGFR2 (1:20; Sc-6251 mouse IgG1; Santa Cruz Biotechnol-
ogy), anti-pVEGFR2 Tyr 1175 (1:20; 2478 rabbit IgG; Cell Signaling
Technology), anti-TTF-1 (1:50; M3575 mouse IgG1; Dako), anti-p63
(1:50; N1604 mouse IgG2a; Dako), anti-CD31 (1:40; DIA310 rat
IgG2a; Dianova, Hamburg, Germany), anti-Ki67 (1:100; SP6 rabbit
IgG; Neomarkers, Fremont, CA, USA), anti-cleaved caspase 3
(1:100; 9661 rabbit IgG; Cell Signaling Technology), anti-ALDH1A1
(1:50; EP1933Y rabbit IgG; Abcam, Cambridge, UK), anti-CD133
(1:10; C24B9 rabbit IgG; Cell Signaling Technology), anti-CD15
(1:25; MC480 rabbit IgM; Abcam), and anti-CA-IX (1:00; ab15086
rabbit IgG; Abcam). For VEGF, VEGFR2, CD31, CD133, CD15, and
CA-IX detection, microwave antigen retrieval was conducted with
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citrate buffer (10 mM, pH 6) for 20 min. For cleaved caspase 3
detection, microwave antigen retrieval with EDTA buffer (pH 8;
Thermo Fisher Scientific, Waltham, MA, USA) was performed for
20 min. For phosphoVEGFR2, TTF-1, p63, Ki67, and ALDH1A1
detection, slides were incubated in Tris–EDTA buffer (pH 9; Thermo
Fisher Scientific) for 20 min at 95°C in a Lab vision PT module
(Thermo Fisher Scientific). After antigen retrieval, sections were
incubated with the primary antibodies diluted in Real Antibody
Diluent (Dako) for 30 min at room temperature. Subsequently, sec-
tions were incubated with the Envision complex (Dako), and the
peroxidase activity was detected by 3,3′-diaminobenzidine. To
detect CD31, a secondary antibody anti-rat immunoglobulins was
applied before the Envision complex. Isotype control antibodies
with no relevant specificity for lung tissue and obtained from the
same species as the primary antibodies (Supplementary Fig S2B) or
omission of the primary antibody were used as negative controls.
Additional controls for VEGF pathway antibodies have been already
published (Pajares et al, 2012).
Quantification of staining for CD31, Ki67, cleaved caspase 3,
ALDH1A1, CD133, CD15, or CA-IX was performed automatically by
the Analysis software (Olympus, Barcelona; Spain). Images were
captured using a Zeiss Axio Imager M1 microscope (Carl Zeiss,
Madrid, Spain). CD31-, ALDH1A1-, CD133-, CD15-, or CA-IX-positive
area was calculated as the ratio of the positive area to total tumor
area. In the case of Ki67, the ratio of positive nuclear area to total
nuclear area was employed. For cleaved caspase 3 quantification,
the ratio of positive cells to total tumor cells was calculated. In all
cases, only tumor cell staining was quantified. In order to study the
correlation between CA-IX and ALDH1A1, CD133, or CD15 expres-
sion, immunohistochemistry was performed on serial sections.
Reverse transcription and real-time quantitative PCR
Total RNA was isolated from paired tumor and normal tissue on
slides from paraffin-embedded sections (ten 3-lm-thick sections
per mouse) using the RecoverAll Total Nucleic Acid Isolation sys-
tem (Ambion, Life Technologies, Madrid, Spain). Five hundred
nanograms of total RNA was reverse-transcribed to cDNA using
SuperScript III (Invitrogen, Life Technologies, Madrid, Spain) and
random hexamers (Applied Biosystems, Life Technologies, Madrid,
Spain). Quantitative RT-PCR for ALDH1A1, CD133, CD15, and
HIF-1a (primers sequences are listed in Supplementary Table S1)
was performed using the SYBR Green kit (Applied Biosystems, Life
Technologies) on an ABI PRISM 7300 real-time thermal cycler
(Applied Biosystems, Life Technologies). All samples were run in
triplicate and the genes of interest were normalized to the reference
gene (GUSB) and the paired normal tissue using the 2DDCt method.
Statistical analysis
The normal distribution of the data was tested by the D’Agostino–
Pearson test. Statistical differences between groups were evaluated
by Student’s t test or the Mann–Whitney U test according to data nor-
mality. Correlation analysis was performed by the Spearman rank
test. Kaplan–Meier curves and the log-rank test were used to analyze
differences in survival time. Differences were considered statistically
significant when P values were <0.05. The statistical analysis was
performed using SPSS v. 17.0 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism v5.0 software (La Jolla, CA, USA).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
Acknowledgments
The authors thank Gabriel de Biurrun, Cristina Sainz, Amaya Lavın, Joaquin Ur-
diales (all from the Division of Oncology, CIMA), and the Morphology Depart-
ment of CIMA for technical support. We thank Dr. Gorka Bastarrika
(Department of Radiology, University Hospital of Navarra) for his help in the
interpretation of CT scans and Dr. Anne-Marie Bleau (Division of Oncology,
CIMA) for helpful discussions and her expertise in the stem cell field.
This work was supported by “UTE project CIMA”; European Union (Cure-
lung; HEALTH-F2-2010-258677); Spanish Government, Instituto de Salud Carlos
III (ISCIII; PI11/00618, PI10/00166, and PI13/00806); Red Tematica de Investi-
gacion Cooperativa en Cancer (RTICC; RD12/0036/0040), Spanish Ministry of
Economy and Competitiveness & European Regional Development Fund
(ERDF) Una manera de hacer Europa; and Government of Navarra, Depart-
ment of Health (39/2007). ML received a fellowship from the ISCIII, and JA was
funded by the Sara Borrell Program from the ISCIII.
Author contributions
ML, JA, OC, MJP, IZ, and DA performed experimental work. RP, LMM, ML, and JA
planned and supervised the project, performed data analysis, and wrote the
manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
The paper explained
Problem
The VEGF pathway is a clinically validated antiangiogenic target for
advanced NSCLC. Hence, thousands of lung cancer patients are
expected to be enrolled in clinical trials assessing the use of VEGF-
pathway-targeted drugs. Since the prognostic relevance of the VEGF
pathway in NSCLC patients is dependent on tumor histology, a rigor-
ous assessment of the biological response to antiangiogenic drugs on
the two main histologies of NSCLC is essential.
Results
Using mouse models of NSCLC-specific histological subtypes: ADC and
SCC, we demonstrate here the contrasting responses of NSCLC to an-
tiangiogenic therapies depending on histology. We have shown that
two anti-VEGFR2 therapies (sunitinib and DC101) elicited vascular
trimming and tumor stabilization in ADC tumors. In contrast, VEGFR2
blockade in SCC caused hyperproliferation of tumor cells and
increased the expression of stem cell markers, independently of intra-
tumoral hypoxia.
Impact
A major new finding of the present study is that antiangiogenic thera-
pies induce contrasting responses in NSCLC depending on the histo-
logical subtype. Our findings further implicate the induction of stem
cell population and tumor hyperproliferation as a mechanism for
tumor progression in SCC treated with antiangiogenic drugs. These
results have important clinical implications in the design of future an-
tiangiogenic therapeutic trials and emphasize the need for precaution
when considering the possibility of enrolling SCC patients in clinical
trials evaluating antiangiogenic drugs.
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